Walking a Fine Line<br />By Rev Shark<br />RealMoney.com Contributor<br />3/12/2008 9:09 AM EDT <br /><br /><br />Every story can be told in different ways. <br />-- Greek proverb<br /><br />The headlines this morning are blaring with talk about the biggest market gain in five years. Indeed it was a very good point move, but we aren't even back up to where we were three days ago and we are still buried in an ugly downtrend. <br /><br />Yes, the big bounce yesterday on good volume is certainly a technical positive and bodes well for some future upside, but it by no means is an indication that we have turned the corner and that it will be clear sailing from here. <br /><br />Big, sudden spikes are the nature of bear markets; often they will be intense enough and last long enough to cause people to believe that the worst is over. It is the restoration of hope that ultimately causes the most pain in a bear market. <br /><br />At this juncture we are faced with an interesting balancing act. While we certainly can't start believing that a major turn is taking place, we want to give this bounce plenty of room to play out. Investors are so negative and so underinvested that they are very poorly positioned for strength at this point. That is going to help support us, and if we actually can hold up for a while, some of the money on the sidelines is going to creep back in on investors' fear that they might be left behind if something develops. <br /><br />The market is still very sensitive to news and can react swiftly is something negative hits, but we have had so much negative lately that it doesn't take much good news to bring in the buyers. With the Fed interest rate decision coming up next week, many may feel that now is not the time to try to fight the Fed. <br /><br />I'll be watching to see how well we hold, and if the bulls can hang in, I'll add some long exposure. I'm still holding very high levels of cash, but I'm looking for some opportunities on the long side. <br />-----------------------------<br />Ülespoole avanevad:<br /><br />In reaction to strong earnings/guidance: HDL +26.1%, QTWW +17.5%, TLCV +15.3%, MBLX +11.7%, JASO +9.4%, JCG +5.6% (also upgraded to outperform at Raymond James), AEO +4.1%, DXCM +3.7%, TTWO +2.6%, CAT +2.3%, EXLS +1.9%, STLD +1.6%... Select European financial names showing strength: UBS +3.6%.... Other news: TWTI +40.8% (confirms HPV clinical trial achieves primary clinical endpoints), CRXX +20.9% (says drug candidate CRx-191 demonstrates 'positive' phase 2 results in psoriasis), DNDN +11.4% (FDA agrees to amend Special Protocol Assessment for Phase 3 IMPACT Study of PROVENGE), SIMO +7.9% (announces $40 mln stock repurchase program), FLDR +6.5% (announces a supply agreement with Lowe's), TASR +2.8% (announces United States Air Force Security Forces to deploy TASER X26 devices), CAM +2.7% (announces $650 mln contract for subsea equipment offshore West Africa), BHP +2.3%, RTP +2.2%, WWE +1.0% (Cramer makes positive comments on MadMoney)... Analyst upgrades: TMA +31.4% (upgraded to Peer Perform at Bear Sterns), DMND +4.1% (upgraded to Buy from Neutral at Piper Jaffray), ABH +2.3% (upgraded to Mkt Perform at BMO).<br /><br />Allapoole avanevad:<br /><br />In reaction to weak earnings/guidance: DIVX -28.4% (also downgraded to Source of Fund at ThinkEquity and downgraded to Mkt Perform at Barrington), HUM -20.8%, DECC -11.4%, AMIE -10.5%, PED -8.7%, PSS -6.3%, VIP -5.0%, CODI -4.6%, ICFI -4.5%, XOMA -3.9%, SVNT -3.0%, AKRX -2.3%, ENZ -2.3%, GLBC -2.0%, IRETS -2.0%, GPOR -1.9%, AAON -1.4%... Health insurance names showing continued weakness following HUM's (-20.8%) warning: WCG -12.1%, CVH -8.7%, HNT -7.5% (also hearing removed from Conviction Buy list at tier 1 firm), UNH -6.6%, AET -6.2%, CI -3.9%... Other news: PGNX -48.3% (update on Phase III clinical trial of intravenous methylnaltrexone for postoperative ileus, treatment did not achieve the primary end point of the study), BLUD -24.1% (to acquire BioArray Solutions; expects this acquisition to be materially dilutive to EPS for several years), CPHD -9.7% (comments on study regarding MRSA surveillance and reaffirms guidance), DPM -3.9% (announces commencement of public offering of common units)... Analyst downgrades: PKOH -9.2% (downgraded to Hold at Morgan Joseph), KLAC -5.6% (downgraded to Underperform at Oppenheimer), SEH -3.7% (downgraded to Equal Weight at First Analysis), LVLT -3.0% (downgraded to Hold at Jefferies), UAUA -2.6% (downgraded to Underweight at JPMorgan), LCC -2.1% (downgraded to Underweight at JPMorgan).